H.C. Wainwright lowered the agency’s worth goal on Nurix Therapeutics (NRIX) to $34 from $36 and retains a Purchase score on the shares. Nurix final week reported a Q2 internet lack of (52c) per share, barely narrower than the agency’s beforehand estimated internet lack of (62c) per share, the analyst tells buyers in a analysis be aware. The agency is factoring in better working bills shifting ahead.
Revealed first on TheFly – the final word supply for real-time, market-moving breaking monetary information. Strive Now>>
See right now’s best-performing shares on TipRanks >>
Learn Extra on NRIX:
Disclaimer & DisclosureReport an Situation